Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 2(2)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07125066Phase 1Enrolling By Invitation

An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)

Role: collaborator

NCT06773026Phase 2Recruiting

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Role: collaborator

NCT05668754Phase 2Completed

Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Role: lead

NCT03460652Phase 3Completed

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

Role: lead

NCT03292952Phase 3Completed

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

Role: lead

All 5 trials loaded